Valchlor (mechlorethamine) gel

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved August 2013

Specific Treatments:

Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma

Therapeutic Areas

Find Related Trials for The Following Conditions

General Information

Valchlor is a gel formulation of mechlorethamine, an alkylating agent which inhibits rapidly proliferating cells.

Valchlor is specifically indicated for the topical treatment of Stage IA and IB mycosisfungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

Valchlor is supplied as a gel for topical administration. The recommendation is to apply a thin film of Valchlor gel once daily to affected areas of the skin. Upon improvement, treatment with Valchlor can be restarted at a reduced frequency of once every 3 days. If reintroduction of treatment is tolerated for at least one week, the frequency of application can be increased to every other day for at least one week and then to once daily application if tolerated.

Clinical Results

FDA Approval
The FDA approval of Valchlor gel was based on a randomized, multicenter, observer-blind, active-controlled, non-inferiority clinical trial of 260 subjects with Stage IA, IB, and IIA mycosisfungoides-type cutaneous T-cell lymphoma (CTCL) who had received at least one prior skin-directed therapy. The subjects were stratified based on Stage (IA vs. IB and IIA) and then randomized to receive Valchlor 0.016% (equivalent to 0.02% mechlorethamineHCl) or Aquaphor-based mechlorethamine HCl 0.02% ointment (Comparator). Eighteen subjects were excluded from the efficacy analysis due to protocol violations involving randomization at a single site. Study drug was applied topically on a daily basis for 12 months. Concomitant use of topical corticosteroids was not permitted during the study. The mean daily usage of Valchlor gel was 2.8 g. The maximum daily usage was 10.5 g. Subjects were evaluated for a response on amonthly basis for the first 6 months and then every 2 months for the last 6 months using the Composite Assessment of Index Lesion Severity (CAILS) score. A response was defined as greater than or equal to 50% reduction in baseline CAILS score which was confirmed at the next visit at least 4 weeks later. A complete response was defined as a confirmed CAILS score of 0 (no symptoms). Subjects were also evaluated using the Severity Weighted Assessment Tool (SWAT). A response was defined as greater than or equal to 50% reduction in baseline SWAT score which was confirmed at the next visit at least 4 weeks later. Sixty percent (60%) of the subjects on the Valchlor arm and 48% of subjects on the comparator arm achieved a response based on the CAILS score. Valchlor was non-inferiorto the comparator based on a CAILS overall response rate ratio of 1.24. Complete responses constituted a minority of the CAILS or SWAT overall responses.The onset of CAILS overall cresponse for both treatment arms showed a wide range from 1 to 11 months.

Side Effects

Adverse events associated with the use of Valchlor may include, but are not limited to, the following:

  • dermatitis
  • pruritus
  • bacterial skin infection
  • skin ulceration or blistering
  • hyperpigmentation

Mechanism of Action

Valchlor is a gel formulation of mechlorethamine, also known as nitrogen mustard, an alkylating agent which inhibits rapidly proliferating cells.

Additional Information

For additional information regarding Valchlor or Stage IA, IB, and IIA mycosisfungoides-type cutaneous T-cell lymphoma, please visit the Valchlor web page.